John Anson, Paul Kenny

Apr 09, 2018

Oxford Gene Technology has announced that it has appointed John Anson as CEO, who previously served as executive VP of research and development. He will be replacing Mike Evans, who has become a non-executive director of OGT's board 

In addition, OGT has appointed Paul Kenny as executive VP of regulatory and medical affairs. Kenny previously served as head of regulatory affairs at The Binding Site. 

More Like This

Feb 19, 2019

Anthony Schmidt

Circulogene named Anthony Schmidt as its medical director. He will lead the lab's precision medicine initiatives and educate the medical community about the firm's technologies. Schmidt was most recently pathology chair and lab medical director for Mississippi Baptist Healthcare System. 

Feb 19, 2019

Leo Grady

Paige.AI has named Leo Grady as its CEO and a board member. The New York-based startup was launched last year and leverages technology developed by its Cofounder and CSO Thomas Fuchs to digitize pathology slides from Memorial Sloan Kettering Cancer Center. The company has a licensing agreement with MSK and said it is on its way to digitizing 5 million pathology slides from the center. Grady was previously senior vice president of engineering for HeartFlow. Prior to that, he was at Siemens where he served in a variety of scientific and leadership positions. 

Feb 19, 2019

Gabrielle Wolfson, Denise Morrison

Gabrielle Wolfson has been appointed Quest Diagnostics' senior vice president and chief information and digital officer. She joins the company fron Xerox where she had been CIO since 2016. Before that, she was CIO at Wyndham Hotels and Resorts and was CIO at Integra Life Sciences and Par Pharmaceutical. 

Quest also announced Denise Morrison has been elected to its board, effective Feb. 18. Morrison was president and CEO of Campbell Soup Company from 2011 to 2018. 

Feb 12, 2019

Sharon Klugewicz

Chembio said in a filing with the US Securities and Exchange Commission that Sharon Klugewicz is resigning as its senior vice president and chief quality and regulatory officer on Feb. 22.

Feb 06, 2019

Peter Kaspar

First Light Diagnostics has appointed Peter Kaspar to its board of directors. Kaspar has been a member of bioMérieux's executive committee, where he was responsible for the firm's molecular diagnostics unit, global research and development, and later the microbiology unit. Kaspar previously held executive roles within several global organizations, including the Foundation for Innovative Diagnostics.

Feb 06, 2019

Patti Connolly, Paul Brenner

RenalytixAI has appointed Patti Connolly as its VP of clinical and scientific affairs. Connolly will lead the firm's recruitment efforts for the prospective clinical utility study for its KidneyIntelX assay, which the firm plans to begin in Q4 2019. Prior to RenalytixAI, Connolly served as clinical services director at Pearl Pathways.

RenalytixAI has also appointed and Paul Brenner to the firm's advisory board. Brenner currently serves as a computer science faculty member at the University of Notre Dame and associate director of Notre Dame's Center for Research Computing. Brenner also serves as a senior reserve advisor to the Air Force Cyber College Commandment.

Jan 29, 2019

Esther Abels

PathAI announced Esther Abels has been appointed its vice president of regulatory and clinical affairs and strategic business development. She will direct the company's development of medical devices and lead its regulatory strategy. Abels was most recently a senior direcgtor at Philips where she led efforts to gain US Food and Drug Administration approval for whole-slide imaging systems. 

Jan 29, 2019

Jean-Francois Yale

Diagnos has appointed Jean-Francois Yale to its board. Yale is an endocrinologist and is currently a professor of medicine at McGill University's department of medicine. He chaired the clinical and scientific section of the Canadian Diabetes Association from 1992-1994.

Jan 28, 2019

Robert Yates, Martin Madaus

Ortho Clinical Diagnostics announced that its board of directors has appointed Robert Yates as chairman and chief executive officer effective Feb. 12. Yates will succeed Martin Madaus, who is retiring after serving as chairman and CEO of Ortho since June 2014. 

Yates is currently Ortho's president and has served as a director on the company's board since June 2014. He was previously the chief operating officer and a member of Ortho's executive leadership team for more than four years.

Jan 25, 2019

John Steuart, Gail Marcus

John Steuart has resigned from Natera's board of directors. The board has also appointed Gail Marcus as chair of the audit committee. She joined Natera's board in March 2017 and currently serves as chair of the nominating and corporate governance committee.

Jan 24, 2019

Greg Thompson

GeneCapture has appointed Greg Thompson as its chief operating officer. Thompson will oversee the product design, commercialization, and medical device approvals for the firm's portable and rapid diagnostic for the point-of-care market. Thompson previously served as VP of design in the medical division and VP of global product design and development at Sanmina. Thompson earned a BSEE degree in computer engineering from North Dakota State University.

Jan 23, 2019

Thomas Montine, Jon Morrow

OptraScan announced the expansion of its medical advisory board with two appointments — Thomas Montine, chairman of the department of pathology at Stanford University School of Medicine, and Jon Morrow, chairman of the department of pathology at Yale School of Medicine.

The firm's medical advisory board already includes Jiaoti Huang, professor and chairman of the department of pathology at Duke University; Allen Gown, founder and medical director at Phenopath; and Abul Abbas, chairman of the department of pathology at University of California, San Francisco.

Jan 22, 2019

Michael Rasche

Metabolon has appointed Michael Rasche as its president of international business. Rasche will lead the firm's international business activities with a focus on customer and team expansion. Prior to Metabolon, Rasche acted as chief commercial officer at Definiens. Before Definiens, Rasche served as corporate VP of global commercial operations at Ayoxxa. He has also held leadership positions at Dako (now Agilent), Roche, and Bayer Diagnostics in Europe, as well as North and South America.

Jan 18, 2019

TJ Johnson, John Lubniewski

HTG Molecular Diagnostics has announced that TJ Johnson, the firm's current CEO, will assume the role of executive chairman of its board of directors. John Lubniewski, HTG's president and chief operating officer, will succeed Johnson as CEO. In addition, Ann Hanham will assume the role of lead independent director at the end of Q1 2019.

Lubniewski has served as HTG's president and COO since April 2018, joining the firm in 2011 as chief business officer. Before HTG, Lubniewski served in several leadership roles at Ventana, including senior VP and life cycle leader for platforms and clinical assays, as well as head of global marketing. Prior to Ventana, Lubniewski worked at Corning for over a decade in a variety of roles.

Jan 14, 2019

Jack Frausing

US BioTek Laboratories announced the appointment of Jack Frausing as president and CEO. Frausing assumes the leadership role from co-founder and current president Raymond Suen and his co-founder and wife Margaret Suen, the current executive vice president. The addition of Frausing is the first step in a plan to expand the company's testing and reporting capabilities and expand sales and marketing to reach and service a growing customer base. Raymond and Margaret Suen will continue to be active in the company to facilitate a smooth transition.